| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 抗病毒类(元) | 4,521,368.35 | 8,736,658.05 | 3,848,896.25 | 13,390,760.40 | 8,243,351.30 |
| 抗生素类(元) | 17,560,804.64 | 37,014,447.76 | 14,939,303.56 | 63,891,933.25 | 30,115,773.80 |
| 利尿剂类(元) | 1,043,180.15 | 1,623,453.85 | 352,193.52 | 40,863,301.12 | 39,292,604.19 |
| 免疫调节类(元) | 2,483,034.18 | 4,513,683.79 | 1,871,532.73 | 2,889,439.68 | 1,355,191.29 |
| 消化类(元) | 4,625,353.79 | 8,709,013.22 | 4,395,771.51 | 10,907,082.47 | 6,675,326.70 |
| 心脑血管类(元) | 268,836,321.87 | 427,777,185.12 | 202,821,102.35 | 359,524,805.54 | 164,319,131.90 |
| 原料药及中间体(元) | 5,196,575.50 | 7,566,955.76 | 2,803,415.91 | 3,406,592.95 | 199,823.00 |
| 其他(元) | 1,745,196.98 | 6,166,479.21 | 4,427,181.96 | 21,103,302.85 | 10,440,784.24 |
| 营业成本(元) | |||||
| 抗病毒类(元) | 3,954,909.35 | - | 2,931,549.80 | - | - |
| 抗生素类(元) | 5,232,686.31 | - | 3,755,866.06 | 25,780,471.95 | 11,745,268.21 |
| 利尿剂类(元) | 290,820.44 | - | 163,105.55 | - | 3,387,487.78 |
| 免疫调节类(元) | 775,625.83 | - | 591,313.57 | - | - |
| 消化类(元) | 3,306,427.47 | - | 2,880,318.80 | - | - |
| 心脑血管类(元) | 20,374,143.75 | 35,739,715.41 | 17,848,304.69 | 32,806,988.18 | 13,947,864.19 |
| 原料药及中间体(元) | 50,354,260.19 | - | 2,275,910.24 | - | - |
| 其他(元) | 1,512,507.75 | - | 4,058,622.15 | - | - |
| 毛利(元) | |||||
| 抗病毒类(元) | 566,459.00 | - | 917,346.45 | - | - |
| 抗生素类(元) | 12,328,118.33 | - | 11,183,437.50 | 38,111,461.30 | 18,370,505.59 |
| 利尿剂类(元) | 752,359.71 | - | 189,087.97 | - | 35,905,116.41 |
| 免疫调节类(元) | 1,707,408.35 | - | 1,280,219.16 | - | - |
| 消化类(元) | 1,318,926.32 | - | 1,515,452.71 | - | - |
| 心脑血管类(元) | 248,462,178.12 | 392,037,469.71 | 184,972,797.66 | 326,717,817.36 | 150,371,267.71 |
| 原料药及中间体(元) | -45,157,684.69 | - | 527,505.67 | - | - |
| 其他(元) | 232,689.23 | - | 368,559.81 | - | - |
| 毛利率(%) | |||||
| 抗病毒类(%) | 12.53 | - | 23.83 | - | - |
| 抗生素类(%) | 70.20 | - | 74.86 | 59.65 | 61.00 |
| 利尿剂类(%) | 72.12 | - | 53.69 | - | 91.38 |
| 免疫调节类(%) | 68.76 | - | 68.40 | - | - |
| 消化类(%) | 28.52 | - | 34.48 | - | - |
| 心脑血管类(%) | 92.42 | 91.65 | 91.20 | 90.87 | 91.51 |
| 原料药及中间体(%) | -868.99 | - | 18.82 | - | - |
| 其他(%) | 13.33 | - | 8.32 | - | - |
| 收入构成(%) | |||||
| 抗病毒类(%) | 1.48 | 1.74 | 1.63 | 2.60 | 3.16 |
| 抗生素类(%) | 5.74 | 7.37 | 6.34 | 12.38 | 11.55 |
| 利尿剂类(%) | 0.34 | 0.32 | 0.15 | 7.92 | 15.08 |
| 免疫调节类(%) | 0.81 | 0.90 | 0.79 | 0.56 | 0.52 |
| 消化类(%) | 1.51 | 1.73 | 1.87 | 2.11 | 2.56 |
| 心脑血管类(%) | 87.85 | 85.20 | 86.14 | 69.68 | 63.04 |
| 原料药及中间体(%) | 1.70 | 1.51 | 1.19 | 0.66 | 0.08 |
| 其他(%) | 0.57 | 1.23 | 1.88 | 4.09 | 4.01 |
| 毛利构成(%) | |||||
| 抗病毒类(%) | 0.26 | 0.00 | 0.46 | 0.00 | 0.00 |
| 抗生素类(%) | 5.60 | 0.00 | 5.57 | 10.45 | 8.98 |
| 利尿剂类(%) | 0.34 | 0.00 | 0.09 | 0.00 | 17.54 |
| 免疫调节类(%) | 0.78 | 0.00 | 0.64 | 0.00 | 0.00 |
| 消化类(%) | 0.60 | 0.00 | 0.75 | 0.00 | 0.00 |
| 心脑血管类(%) | 112.83 | 100.00 | 92.05 | 89.55 | 73.48 |
| 原料药及中间体(%) | -20.51 | 0.00 | 0.26 | 0.00 | 0.00 |
| 其他(%) | 0.11 | 0.00 | 0.18 | 0.00 | 0.00 |